Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Relative Bioavailability of Avenciguat Formulations and Effect of Food/Esomeprazole
NCT06193811Phase 1Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Jan 2024
- Primary completion
- Mar 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of avenciguat in systemic sclerosis (SSc), chronic kidney disease (CKD), diabetic kidney disease (DKD) and 1 more, sponsored by Boehringer Ingelheim. Primary endpoints: Area under the concentration-time curve from time zero to the last quantifiable data point up to 4 days and Maximum measured concentration up to 4 days. Started Jan 2024; status: completed.
02
Drugs
avenciguat
03
Conditions
systemic sclerosis (SSc)chronic kidney disease (CKD)diabetic kidney disease (DKD)Portal Hypertension (PH)
Beyond the preview
Go deeper on NCT06193811.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06193811.